NOVO NORDISK

NVO Public

NYSE exchange • Created Jan 13, 2026

Financial reports

Public filings from SEC EDGAR and company websites.

AI reports

Completed valuation analysis reports.

Last cutoff

Dec 31, 2024

Most recent financial reporting period.

Ticker price

USD 38.58

Updated Mar 6, 2026

Fair value

??? (Subscribe to view)

Updated Mar 9, 2026

AI-generated reports

Track completed analysis reports.

Report name	Report date	Language	Fair value
2026 Analysis	Dec 31, 2024	English	??? (Subscribe to view)

Editorial coverage tied to this company.

Feb 26, 2026

针对此疑问，我们需要从利润结构、产能成本和市场份额三个维度来深度拆解礼来（Eli Lilly）和诺和诺德（Novo Nordisk）的受损程度。

Article

Feb 4, 2026

从逆向思维来看，诺和诺德目前的风险不在于它不够优秀，而在于“优秀的容错率极低”。市场已经把它当成了不会犯错的神，但正如巴菲特所说：“在别人贪婪时恐惧。”

Article

Jan 19, 2026

如果你相信肥胖症和糖尿病的长期治疗需求依然巨大，目前价位更像是“黄金坑”的右侧修复期。但我会建议分批建仓，重点关注2026年口服药物的审批进度。

Article

Public filings from SEC EDGAR and company websites.

Report name	Report date	Language
20241231_en.pdf	Dec 31, 2024	EN